Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
A0A0U1RR11
UPID:
CENL1_HUMAN
Alternative names:
Centromere protein V pseudogene 1
Alternative UPACC:
A0A0U1RR11; Q3ZM64
Background:
Centromere protein V-like protein 1, alternatively known as Centromere protein V pseudogene 1, plays a crucial role in chromosome segregation during cell division. Its precise functions and mechanisms of action are subjects of ongoing research, highlighting its importance in cellular biology.
Therapeutic significance:
Understanding the role of Centromere protein V-like protein 1 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes underscores the potential for developing novel treatments targeting diseases related to cell division abnormalities.